Journal
JOURNAL OF MEDICAL VIROLOGY
Volume 93, Issue 6, Pages 3907-3914Publisher
WILEY
DOI: 10.1002/jmv.26655
Keywords
AIDS; diffuse large B‐ cell lymphoma; lymphocyte‐ to‐ monocyte ratio; platelet‐ to‐ lymphocyte ratio; prognosis
Categories
Funding
- 13th Key Science and Technology Five Year Plan of China [2018ZX10302104]
- National Natural Science Foundation of China [81873761]
Ask authors/readers for more resources
Both LMR (lymphocyte-to-monocyte ratio) and PLR (platelet-to-lymphocyte ratio) have been found to be prognostic indicators in patients with AR-DLBCL (AIDS-related diffuse large B-cell lymphoma). Lower LMR is independently associated with poorer overall survival in these patients.
The lymphocyte-to-monocyte ratio (LMR) and platelet-to-lymphocyte ratio (PLR) have been reported to be useful for predicting the prognosis of various malignancies, including diffuse large B-cell lymphoma (DLBCL). However, little is known about the role of LMR and PLR in the prognosis of DLBCL patients with human immunodeficiency virus (HIV) infection. We retrospectively evaluated the prognostic value of the LMR and PLR in patients with newly diagnosed AIDS-related diffuse large B-cell lymphoma (AR-DLBCL) who were treated with CHOP-like chemotherapy at a single institution. In 33 AR-DLBCL patients, the median follow-up period was 32 months (range: 7-85 months), with an estimated 2-year overall survival (OS) rate of 79.9%. The univariate analysis confirmed the LMR <= 2.74 (p = .015), PLR >= 337.7 (p = .019), and moderate anemia (p = .045) were associated with inferior survival. The independent significant association between low LMR and poor OS in the multivariate analysis was identified (HR: 0.033, 95% CI: 0.001-0.853, p = .040). However, PLR (p = .459) and moderate anemia (p = .102) did not retain an independent significance in the multivariate analysis. Moreover, compared with the high-LMR group, patients with low-LMR more frequently had B symptoms (p = .010) and lower CD4+T cell count (p < .001). The pretreatment LMR may be an effective prognostic factor for predicting OS in patients with AR-DLBCL.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available